Vasculitis

ICYMI: EULAR guidelines rec starting prednisone dose in #PMR to be between 12.5-25mg/d. A cross sectional study of 138 pts (63M, 75F, age 73.4 yes) saw the mean starting dose to be 19.2±7.7 mg.  https://t.co/Yf3yqRRMCK

Links:

Dr. John Cush @RheumNow( View Tweet )

Jul 29, 2021
ICYMI While myeloperoxidase (MPO) Abs are seen in idiopathic pulmonary fibrosis (IPF), only 7–23% develop vasculitis. Study of 58 pts w/ IPF & MPO Abs - UIP most frequent ILD pattern, 13 had rheumatic dz; MPO Abs did not change survival of UIP/IPF pts https://t.co/RXXIPUBMBT https://t.co/sJpbzIbBJt

Links:

Dr. John Cush @RheumNow( View Tweet )
Jul 29, 2021
While myeloperoxidase (MPO) Abs are seen in idiopathic pulmonary fibrosis (IPF), only 7–23% develop vasculitis. Study of 58 pts w/ IPF & MPO Abs - UIP most frequent ILD pattern, 13 had rheumatic dz; MPO Abs did not change survival of UIP/IPF pts https://t.co/RXXIPUBMBT https://t.co/v3KhEaefZD

Links:

Dr. John Cush @RheumNow( View Tweet )
Jul 22, 2021
Drugs capable of inducing drug-associated ANCA vasculitis - mirabegron (Myrbetriq), sofosbuvir (Sovaldi, antiviral), nintedanib (Ofev), hydralazine, propylthiouracil, thiamazole, minocycline, carbimazole, allopurinol, influenza vax.... https://t.co/KhK2w10hs5

Links:

Dr. John Cush @RheumNow( View Tweet )

Jul 20, 2021
artangiogca.jpg

ACR/Vasculitis Foundation Guideline for Giant Cell Arteritis and Takayasu Arteritis

Jack Cush, MD
Jul 19, 2021

The ACR and the Vasculitis Foundation have published their evidence-based recommendations and expert guidance for the management of GCA and Takayasu arteritis. These recommendations address a variety of clinical questions and scenarios including diagnostic testing, imaging, treatments, and

Read Article
ACR/Vasculitis Foundation 2021 Guidelines for ANCA–Associated Vasculitis Chung et al have published the 2021 treatment guidelines for the management of antineutrophil cytoplasmic antibody–AAV, including GPA, MPA, and EGPA. https://t.co/234OQ7klRd https://t.co/33sWq1U55T

Links:

Dr. John Cush @RheumNow( View Tweet )
Jul 15, 2021
ANCA, vasculitis, test

ACR/Vasculitis Foundation 2021 Guidelines for ANCA–Associated Vasculitis

Jack Cush, MD
Jul 14, 2021

Chung et al have published the 2021 treatment guielines for the management of antineutrophil cytoplasmic antibody–associated vasculitis, including granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. These guidelines are put forth by the

Read Article
Plasmapheresis Indications : TTP, HUS, Cryoglobulinemia, Hyperviscosity, Myasthenia gravis, Goodpastures, Catastrophic APL Syn, Chr inflamm demyelinating polyneuropathy, Removal of drugs/toxins, Alveolar hemorrhage, ANCA vasculitis (questionable) https://t.co/uph9Eprlvc https://t.co/FPLOgzZpfB

Links:

Dr. John Cush @RheumNow( View Tweet )
Jul 08, 2021
Textbooks say fever is common in lupus ("36%–86%") BUT IT IS NOT! Lupus is cause of FUO in 5%; Fever is seen in a minority of SLE onsets; Fever occurs w/ SLE complications - vasculitis, pneumonitis/serositis/alveolar hem, CNS, & INFECTION! https://t.co/KvZeo6Q1WY

Links:

Dr. John Cush @RheumNow( View Tweet )

Jul 07, 2021
WATCH: Is blindness with Tocilizumab in GCA a worry? Dr. David Liew ( @drdavidliew) weighs in. #EULAR2021 https://t.co/eFrmbkW9Gy https://t.co/imMaEIczb8

Links:

Dr. John Cush @RheumNow( View Tweet )
Jul 07, 2021
Blindness with Tocilizumab in GCA: Is it a Worry? https://t.co/PJYap294jm https://t.co/q1izGlH68j

Links:

Dr. John Cush @RheumNow( View Tweet )
Jun 28, 2021
RheumNow Podcast square

RheumNow Podcast – Modern Treatment of RA Pregnancy (6.25.2021)

Jack Cush, MD
Jun 25, 2021

Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.

Read Article
Danish population study shows that all cause mortality in GCA is increased 49%,(RR 1.49; CI1.36-1.64) after 1 year but less so at 10 years (RR 1.03: 1.00-1.05). Deaths usually due to infectious, endocrine, cardiovascular, GI diseases https://t.co/p36zDskf6y

Links:

Dr. John Cush @RheumNow( View Tweet )

Jun 25, 2021
French Vasculitis registry studied 354 GPA patients- 25% had hypereosinophilia (HE) ≥ 500; mostly male (73%) w/ most skin dz (49%) peripheral neuropathy (32%) & higher BVAS (21 vs 18, p= 0.01): severe HE had more baseline renal dysfunction https://t.co/G4s3CEavL9

Links:

Dr. John Cush @RheumNow( View Tweet )

Jun 23, 2021
RheumNow Podcast square

RheumNow Podcast - Best of EULAR 2021

Jack Cush, MD
Jun 11, 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article
Rituximab in PMR. Intriguing proof of concept (SB?) RCT (1:1, total n=47 (recent dx 38/relapsing 9)) 17w rapid PNL taper ritux 1g x1 21w: steroid-free remission: 48% v 21% PNL ≤5mg/d: 100% v 54% effect mainly from recent dx pts We do need options! POS0343 #EULAR2021 @RheumNow https://t.co/g6xJekY92O
David Liew @drdavidliew( View Tweet )
Jun 06, 2021
Dr Schapp on nasal Staph Aureus eradication in ANCA vasculitis. Neither the presence or eradication of Staph Aureus appeared to influence the vasculitis @RheumNow #EULAR2021 Abstr#POS0249 https://t.co/bxtaznejNk
Richard Conway @RichardPAConway( View Tweet )
Jun 05, 2021
Dr Marsman presents positive RCT of Rituximab in PMR. GC-free remission 48% vs 21% (p=0.049) GC<=5mg 100% vs 47% (p=0.005) @RheumNow #EULAR2021 Abstr#POS0343 https://t.co/tjkKTS6DMN
Richard Conway @RichardPAConway( View Tweet )
Jun 05, 2021
Blindness with Tocilizumab in GCA: Is it a Worry? Dr. David Liew ( @drdavidliew ) #EULAR2021 https://t.co/xokPqGMEyA https://t.co/NJ3PrFR6nF

Links:

Dr. John Cush @RheumNow( View Tweet )
Jun 04, 2021
Rheum alliance trainee survey (n=302): 87-96% report negative impact of COVID19 on Rheumatology training: -outpatient clinics (79%) -inpatient consultations (59%) -formal teaching (55%) -procedures (53%) and -ultrasonography (36%) #POS0051 @RheumNow #EULAR2021 @kristenyoung

Aurelie Najm @AurelieRheumo( View Tweet )

Jun 03, 2021
So it comes down to the grand question: how on earth do we actually monitor disease activity?? "We still don't have a failsafe algorithm... relapse is both underdiagnosed & overdiagnosed" - @Sarah_L_Mackie The challenge lots of good people are working on! #EULAR2021 @RheumNow https://t.co/PUa6Ly1DQw
David Liew @drdavidliew( View Tweet )
Jun 03, 2021
Drug-induced ANCA-associated vasculitis: here are the ones to look for👇 - hydralazine - PTU - penicillamine - thiamazole - sofosbuvir - minocycline - carbimazole (but then a few others floating about!) VigiBase data POS0118 #EULAR2021 @RheumNow https://t.co/ujgJAJQeKY
David Liew @drdavidliew( View Tweet )
Jun 03, 2021
Fascinating talk by Dr Tombetti on the potential use of arterial wall derived microvesicles collected from plasma as a means of non-invasive liquid biopsy in vasculitis @RheumNow #EULAR2021 Abstr#OP0056 https://t.co/Y6UO2mpjV0
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2021
Do look out for Abst #OP0057 today 2/6/21 1645 CEST #EULAR2021. We propose a data-driven algorithm for #rituximab maintenance in #ANCA #vasculitis to avoid excessive retreatment and low IgG @RheumJArn @edvital P. Emery @LeedsMedHealth @LTHTResearch @LeedsHospitals @LeedsBRC https://t.co/XRR0NFnpMu
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 02, 2021
Dr Sanchez-Bilbao presents surprising data that tocilizumab may improve even permanent vision loss in GCA @RheumNow #EULAR2021 Abstr#OP0065 https://t.co/oFGNZ04oKr
Richard Conway @RichardPAConway( View Tweet )
Jun 02, 2021

Recent Blogs

ACR20 Pearls Part 3: Pragmatic Applications for Managing Vasculitis

Kathryn H. Dao, M.D.
Feb 11, 2020
Giant-Cell_Vasculitis.jpg
While the ACR prepares to publish its new guidelines for the diagnosis and management of vasculitis in the Spring of 2020, Dr. John Stone presented his own perspectives on the practical management of vasculitis during the 2019 ACR meeting in Atlanta.  He acknowledged that what may be pearls one day, may be disproven with data in the future.  Read Post

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2021 All Rights Reserved.

×